Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient
Psoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. The lesions are typically characterized by sharply demarcated, erythematous plaques covered with silvery scales. Treatment options include topical agents, phototherapy, systemic the...
Saved in:
| Main Authors: | Jianhao Ke, Meiliang Guo, Xuan Zhao, Na Liu, Qinqin Meng, Hui Deng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573495/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia
by: Katie K. Lovell, et al.
Published: (2025-06-01) -
Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01) -
Ponatinib-induced psoriasis treated with tildrakizumab
by: Kyle Mueller, BA, et al.
Published: (2025-08-01) -
Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01) -
Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)